Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome–Associated Variants
Circulation: Genomic and Precision Medicine · 2024
DOI: 10.1161/circgen.124.004569 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Genomic and Precision Medicine, 2024. Verfasst von Joanne G Ma und 19 weiteren Autor:innen. Beteiligte Einrichtung: Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia (J.G.M., J.I…. Hauptthemen laut MEDLINE: Brugada Syndrome, NAV1.5 Voltage-Gated Sodium Channel. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NHGRI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Brugada syndrome is an inheritable arrhythmia condition that is associated with rare, loss-of-function variants in SCN5A . Interpreting the pathogenicity of SCN5A missense variants is challenging, and ≈79% of SCN5A missense variants in ClinVar are currently classified as variants of uncertain significance. Automated patch clamp technology enables high-throughput functional studies of ion channel variants and can provide evidence for variant reclassification. METHODS: An in vitro SCN5A –Brugada syndrome automated patch clamp assay was independently performed at Vanderbilt University Medical Center and Victor Chang Cardiac Research Institute. The assay was calibrated according to ClinGen Sequence Variant Interpretation recommendations using high-confidence variant controls (n=49). Normal and abnormal ranges of function were established based on the distribution of benign variant assay results. Odds of pathogenicity values were derived from the experimental results according to ClinGen Sequence Variant Interpretation recommendations. The calibrated assay was then used to study SCN5A variants of uncertain significance observed in 4 families with Brugada syndrome and other arrhythmia phenotypes associated with SCN5A loss-of-function. RESULTS: Variant channel parameters generated independently at the 2 research sites showed strong correlations, including peak I Na density ( R 2 =0.86). The assay accurately distinguished benign controls (24/25 concordant variants) from pathogenic controls (23/24 concordant variants). Odds of pathogenicity values were 0.042 for normal function and 24.0 for abnormal function, corresponding to strong evidence for both American College of Medical Genetics and Genomics/Association for Molecular Pathology benign and pathogenic functional criteria (BS3 and PS3, respectively). Application of the assay to 4 clinical SCN5A variants of uncertain significance revealed loss-of-function for 3/4 variants, enabling reclassification to likely pathogenic. CONCLUSIONS: This validated high-throughput assay provides clinical-grade functional evidence to aid the classification of current and future SCN5A –Brugada syndrome variants of uncertain significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia (J.G.M., J.I.V., C.-A.N.).
- School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia (J.G.M., J.I.V., C.-A.N.).
- Vanderbilt University School of Medicine, Nashville, TN (M.J.O., A.M.).
- Clinical Genomics Laboratory, Center for Population Genomics, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia (E.R., J.I.).
- Murdoch Children's Research Institute, Melbourne, Victoria, Australia (E.R., J.I.).
- Oxford Genetics Laboratories, Churchill Hospital, Oxford, United Kingdom (K.L.T.).
ORCID-Profile: Joanne G Ma, Matthew J O'Neill, Ebony Richardson, Kate L Thomson, Jodie Ingles, Ayesha Muhammad, Giovanni Davogustto, Katherine C Anderson, M Benjamin Shoemaker, Andrew B Stergachis, Brendan J Floyd, Kyla Dunn, Victoria N Parikh, Henry Chubb, Mark J Perrin, Jamie I Vandenberg, Chai-Ann Ng
Förderung
- NIGMS NIH HHS
- NHGRI NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Ma, J. G., O'Neill, M. J., Richardson, E., Thomson, K. L., Ingles, J., Muhammad, A., Solus, J. F., Davogustto, G., Anderson, K. C., Shoemaker, M. B., Stergachis, A. B., Floyd, B. J., Dunn, K., Parikh, V. N., Chubb, H., Perrin, M. J., Roden, D. M., Vandenberg, J. I., Ng, C. A., & Glazer, A. M. (2024). Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome–Associated Variants. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.124.004569
Vancouver
Ma JG, O'Neill MJ, Richardson E, Thomson KL, Ingles J, Muhammad A, et al. Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome–Associated Variants. Circulation: Genomic and Precision Medicine. 2024. doi:10.1161/circgen.124.004569
BibTeX
@article{Ma2024,
author = {Ma, Joanne G and O'Neill, Matthew J and Richardson, Ebony and Thomson, Kate L and Ingles, Jodie and Muhammad, Ayesha and Solus, Joseph F and Davogustto, Giovanni and Anderson, Katherine C and Shoemaker, M Benjamin and Stergachis, Andrew B and Floyd, Brendan J and Dunn, Kyla and Parikh, Victoria N and Chubb, Henry and Perrin, Mark J and Roden, Dan M and Vandenberg, Jamie I and Ng, Chai-Ann and Glazer, Andrew M},
title = {Multisite Validation of a Functional Assay to Adjudicate SCN5A Brugada Syndrome–Associated Variants},
journal = {Circulation: Genomic and Precision Medicine},
year = {2024},
doi = {10.1161/circgen.124.004569}
}
EUVIMED